Intravenous Infusion of the Novel HNO Donor BMS-986231 Is Associated With Beneficial Inotropic, Lusitropic, and Vasodilatory Properties in 2 Canine Models of Heart Failure
Recommended Citation
Hartman JC, del Rio CL, Reardon JE, Zhang K, Sabbah HN. Intravenous infusion of the novel hno donor bms-986231 is associated with beneficial inotropic, lusitropic, and vasodilatory properties in 2 canine models of heart failure. JACC Basic Transl Sci. 2018;3(5):625-638.
Document Type
Article
Publication Date
10-1-2018
Publication Title
JACC Basic Transl Sci
Abstract
The effects of the nitroxyl donor BMS-986231 on hemodynamics, left ventricular (LV) function, and pro-arrhythmic potential were assessed using canine heart failure models. BMS-986231 significantly (p < 0.05) increased LV end-systolic elastance, pre-load-recruitable stroke work, ejection fraction, stroke volume, cardiac output, ratio of early-to-late filling time integrals, and early mitral valve inflow velocity deceleration time. BMS-986231 significantly decreased LV filling pressures, end-diastolic stiffness, the time-constant of relaxation, end-diastolic wall stress, systemic vascular resistance, and myocardial oxygen consumption. BMS-986231 had little effect on heart rate and did not induce de novo arrhythmias. Thus, BMS-986231 has beneficial inotropic, lusitropic, and vasodilatory effects.
PubMed ID
30456334
Volume
3
Issue
5
First Page
625
Last Page
638
Comments
Original version available at: https://doi.org/10.1016/j.jacbts.2018.07.003